
The elderly population is still underrepresented in clinical trials, with nearly a third of newly registered drugs included an insufficient number of elderly participants, leading to uncertainties regarding safety and effectiveness for prescribers.
The elderly population is still underrepresented in clinical trials, with nearly a third of newly registered drugs included an insufficient number of elderly participants, leading to uncertainties regarding safety and effectiveness for prescribers.
Published: February 28th 2020 | Updated: